# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
39442, Journal, 0, 14, "Ann Intern Med", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasJournal> \"Ann Intern Med\"."
39443, PublicationYear, 17, 21, "2011", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasPublicationYear> \"2011\"."
39444, Title, 134, 257, "Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasTitle> \"Use of twice - daily exenatide in Basal insulin - treated patients with type 2 diabetes : a randomized , controlled trial .\"."
39445, Frequency, 141, 154, "twice - daily", "", 
39446, Exenatide, 155, 164, "exenatide", "", 
39447, Insulin, 168, 181, "Basal insulin", "", 
39448, Type2Diabetes, 206, 221, "type 2 diabetes", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
39449, Randomized, 226, 236, "randomized", "", 
39450, Author, 258, 265, "Buse JB", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Buse JB\"."
39451, Author, 274, 287, "Bergenstal RM", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Bergenstal RM\"."
39452, Author, 290, 298, "Glass LC", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Glass LC\"."
39453, Author, 301, 312, "Heilmann CR", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Heilmann CR\"."
39454, Author, 315, 323, "Lewis MS", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Lewis MS\"."
39455, Author, 326, 333, "Kwan AY", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Kwan AY\"."
39456, Author, 336, 347, "Hoogwerf BJ", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Hoogwerf BJ\"."
39457, Author, 350, 362, "Rosenstock J", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasAuthor> \"Rosenstock J\"."
39458, USA, 464, 467, "USA", "", 
39459, Insulin, 623, 630, "Insulin", "", 
39460, HbA1c_target, 701, 745, "hemoglobin A ₁ ( c ) ( HbA ₁ ( c ) ) targets", "", 
39462, ObjectiveDescription, 760, 893, "To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasObjectiveDescription> \"To test whether twice - daily exenatide injections reduce HbA ₁ ( c ) levels more than placebo in people receiving insulin glargine .\"."
39463, Frequency, 776, 789, "twice - daily", "", 
39464, Exenatide, 790, 799, "exenatide", "", 
39465, HbA1c, 818, 836, "HbA ₁ ( c ) levels", "", 
39466, Placebo, 847, 854, "placebo", "", 
39467, InsulinGlargine, 875, 891, "insulin glargine", "", 
39468, Parallel, 903, 911, "Parallel", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
39469, Randomized, 914, 924, "randomized", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
39470, Placebo, 927, 934, "placebo", "", 
39471, HbA1c, 982, 999, "HbA ₁ ( c ) level", "", 
39472, DoubleBlind, 1056, 1158, "Participants , investigators , and personnel conducting the study were masked to treatment assignments", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
39473, Multicenter, 1230, 1255, "59 centers in 5 countries", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
39474, Type2Diabetes, 1281, 1296, "type 2 diabetes", "", 
39475, HbA1c, 1304, 1321, "HbA ₁ ( c ) level", "", 
39476, Precondition, 1304, 1344, "HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 %", "", "<http://ctro/data#Population_21755> <http://ctro/data#hasPrecondition> \"HbA ₁ ( c ) level of 7 . 1 % to 10 . 5 %\"."
39478, Percentage, 1331, 1332, "%", "", 
39477, Percentage, 1343, 1344, "%", "", 
39482, Precondition, 1354, 1454, "receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )", "", "<http://ctro/data#Population_21755> <http://ctro/data#hasPrecondition> \"receiving insulin glargine alone or in combination with metformin or pioglitazone ( or both agents )\"."
39479, InsulinGlargine, 1372, 1380, "glargine", "", "<http://ctro/data#Medication_21825> <http://ctro/data#hasDrug> <http://ctro/data#InsulinGlargine>."
39480, Metformin, 1410, 1419, "metformin", "", "<http://ctro/data#Medication_21832> <http://ctro/data#hasDrug> <http://ctro/data#Metformin>."
39481, Pioglitazone, 1423, 1435, "pioglitazone", "", "<http://ctro/data#Medication_21839> <http://ctro/data#hasDrug> <http://ctro/data#Pioglitazone>."
39483, Randomized, 1525, 1531, "random", "", 
39484, Exenatide, 1582, 1591, "exenatide", "", "<http://ctro/data#Medication_21811> <http://ctro/data#hasDrug> <http://ctro/data#Exenatide>."
39485, DoseValue, 1594, 1600, "10 µ g", "", "<http://ctro/data#Medication_21811> <http://ctro/data#hasDoseValue> \"10 µ g\"."
39486, Microgram, 1597, 1600, "µ g", "", "<http://ctro/data#Medication_21811> <http://ctro/data#hasDoseUnit> <http://ctro/data#Microgram>."
39487, Frequency, 1601, 1612, "twice daily", "", "<http://ctro/data#Intervention_21781> <http://ctro/data#hasFrequency> \"twice daily\"."
39488, Placebo, 1618, 1625, "placebo", "", "<http://ctro/data#Medication_21818> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
39489, Duration, 1630, 1638, "30 weeks", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasCTduration> \"30 weeks\"."
39490, HbA1c, 1690, 1707, "HbA ₁ ( c ) level", "", 
39491, HbA1c_target, 1774, 1811, "HbA ₁ ( c ) values of 7 . 0 % or less", "", 
39492, HbA1c_target, 1816, 1831, "6 . 5 % or less", "", 
39493, BodyWeight, 1880, 1891, "body weight", "", 
39494, InsulinDose, 1916, 1928, "insulin dose", "", 
39495, Hypoglycemia, 1931, 1943, "hypoglycemia", "", 
87547, FinalNumPatientsArm, 1977, 1980, "112", "", "<http://ctro/data#Arm_21763> <http://ctro/data#hasFinalNumPatientsArm> \"112\"."
39496, NumberPatientsArm, 1984, 1987, "138", "", "<http://ctro/data#Arm_21763> <http://ctro/data#hasNumberPatientsArm> \"138\"."
39500, Exenatide, 1988, 1997, "exenatide", "", 
87548, FinalNumPatientsArm, 2013, 2016, "101", "", "<http://ctro/data#Arm_21772> <http://ctro/data#hasFinalNumPatientsArm> \"101\"."
39499, NumberPatientsArm, 2020, 2023, "123", "", "<http://ctro/data#Arm_21772> <http://ctro/data#hasNumberPatientsArm> \"123\"."
39501, Placebo, 2024, 2031, "placebo", "", 
39502, HbA1c, 2069, 2086, "HbA ₁ ( c ) level", "", "<http://ctro/data#Endpoint_21864> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
87549, Reduction, 2100, 2106, "1 . 74", "", "<http://ctro/data#Outcome_21869> <http://ctro/data#hasChangeValue> \"1 . 74\"."
39505, Percentage, 2107, 2108, "%", "", "<http://ctro/data#Endpoint_21864> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
39507, Exenatide, 2114, 2123, "exenatide", "", 
87550, Reduction, 2128, 2134, "1 . 04", "", "<http://ctro/data#Outcome_21896> <http://ctro/data#hasChangeValue> \"1 . 04\"."
39506, Percentage, 2135, 2136, "%", "", 
39508, Placebo, 2142, 2149, "placebo", "", 
39509, DiffGroupAbsValue, 2181, 2189, "- 0 . 69", "", "<http://ctro/data#DiffBetweenGroups_21924> <http://ctro/data#hasDiffGroupAbsValue> \"- 0 . 69\"."
39510, Percentage, 2190, 2191, "%", "", 
39511, ConfIntervalDiff, 2194, 2228, "95 % CI , - 0 . 93 % to - 0 . 46 %", "", "<http://ctro/data#DiffBetweenGroups_21924> <http://ctro/data#hasConfIntervalDiff> \"95 % CI , - 0 . 93 % to - 0 . 46 %\"."
39512, Percentage, 2197, 2198, "%", "", 
39513, Percentage, 2213, 2214, "%", "", 
39514, Percentage, 2227, 2228, "%", "", 
39515, PvalueDiff, 2233, 2244, "P < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_21924> <http://ctro/data#hasPvalueDiff> \"P < 0 . 001\"."
39516, BodyWeight, 2249, 2255, "Weight", "", "<http://ctro/data#Endpoint_21933> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
39518, Reduction, 2269, 2274, "1 . 8", "", "<http://ctro/data#Outcome_21938> <http://ctro/data#hasChangeValue> \"1 . 8\"."
39520, Kg, 2275, 2277, "kg", "", "<http://ctro/data#Endpoint_21933> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Kg>."
39522, Exenatide, 2283, 2292, "exenatide", "", 
39519, Increment, 2310, 2315, "1 . 0", "", "<http://ctro/data#Outcome_21965> <http://ctro/data#hasChangeValue> \"1 . 0\"."
39521, Kg, 2316, 2318, "kg", "", 
39523, Placebo, 2324, 2331, "placebo", "", 
39524, DiffGroupAbsValue, 2363, 2370, "- 2 . 7", "", "<http://ctro/data#DiffBetweenGroups_21992> <http://ctro/data#hasDiffGroupAbsValue> \"- 2 . 7\"."
39526, Kg, 2371, 2373, "kg", "", 
39527, ConfIntervalDiff, 2376, 2399, "CI , - 3 . 7 to - 1 . 7", "", "<http://ctro/data#DiffBetweenGroups_21992> <http://ctro/data#hasConfIntervalDiff> \"CI , - 3 . 7 to - 1 . 7\"."
39534, InsulinDose, 2427, 2441, "insulin dosage", "", "<http://ctro/data#InsulinDose_22002> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#InsulinDose>. <http://ctro/data#Endpoint_22001> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#InsulinDose_22002>."
39528, Exenatide, 2447, 2456, "exenatide", "", 
39529, Placebo, 2461, 2468, "placebo", "", 
87551, Increment, 2474, 2476, "13", "", "<http://ctro/data#Outcome_22006> <http://ctro/data#hasChangeValue> \"13\"."
39532, BioAndMedicalUnit, 2477, 2482, "U / d", "", "<http://ctro/data#BioAndMedicalUnit_22004> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#BioAndMedicalUnit>. <http://ctro/data#Endpoint_22001> <http://ctro/data#hasBaselineUnit> <http://ctro/data#BioAndMedicalUnit_22004>."
87552, Increment, 2487, 2489, "20", "", "<http://ctro/data#Outcome_22033> <http://ctro/data#hasChangeValue> \"20\"."
39533, BioAndMedicalUnit, 2490, 2495, "U / d", "", 
39535, Hypoglycemia, 2520, 2538, "minor hypoglycemia", "", 
39538, NumberAffected, 2568, 2576, "Thirteen", "", "<http://ctro/data#Outcome_22065> <http://ctro/data#hasNumberAffected> \"Thirteen\"."
39536, Exenatide, 2577, 2586, "exenatide", "", 
39539, NumberAffected, 2602, 2603, "1", "", "<http://ctro/data#Outcome_22092> <http://ctro/data#hasNumberAffected> \"1\"."
39537, Placebo, 2604, 2611, "placebo", "", 
39540, EndPointDescription, 2622, 2670, "discontinued the study because of adverse events", "", "<http://ctro/data#EndPointDescription_22061> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_22060> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_22061>."
39541, PvalueDiff, 2673, 2684, "P < 0 . 010", "", "<http://ctro/data#DiffBetweenGroups_22119> <http://ctro/data#hasPvalueDiff> \"P < 0 . 010\"."
39542, Nausea, 2698, 2704, "nausea", "", "<http://ctro/data#Endpoint_22128> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Nausea>."
39549, PercentageAffected, 2707, 2709, "41", "", "<http://ctro/data#Outcome_22153> <http://ctro/data#hasPercentageAffected> \"41\"."
39559, Percentage, 2710, 2711, "%", "", 
39550, PercentageAffected, 2717, 2718, "8", "", "<http://ctro/data#Outcome_22180> <http://ctro/data#hasPercentageAffected> \"8\"."
39560, Percentage, 2719, 2720, "%", "", 
39543, EndPointDescription, 2725, 2733, "diarrhea", "", "<http://ctro/data#EndPointDescription_22134> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_22133> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_22134>."
39551, PercentageAffected, 2736, 2738, "18", "", "<http://ctro/data#Outcome_22207> <http://ctro/data#hasPercentageAffected> \"18\"."
39561, Percentage, 2739, 2740, "%", "", 
39552, PercentageAffected, 2746, 2747, "8", "", "<http://ctro/data#Outcome_22234> <http://ctro/data#hasPercentageAffected> \"8\"."
39562, Percentage, 2748, 2749, "%", "", 
39544, EndPointDescription, 2754, 2762, "vomiting", "", "<http://ctro/data#EndPointDescription_22139> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_22138> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_22139>."
39553, PercentageAffected, 2765, 2767, "18", "", "<http://ctro/data#Outcome_22261> <http://ctro/data#hasPercentageAffected> \"18\"."
39563, Percentage, 2768, 2769, "%", "", 
39554, PercentageAffected, 2775, 2776, "4", "", "<http://ctro/data#Outcome_22288> <http://ctro/data#hasPercentageAffected> \"4\"."
39564, Percentage, 2777, 2778, "%", "", 
39545, Headache, 2783, 2791, "headache", "", "<http://ctro/data#Endpoint_22143> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Headache>."
39555, PercentageAffected, 2794, 2796, "14", "", "<http://ctro/data#Outcome_22315> <http://ctro/data#hasPercentageAffected> \"14\"."
39565, Percentage, 2797, 2798, "%", "", 
39556, PercentageAffected, 2804, 2805, "4", "", "<http://ctro/data#Outcome_22342> <http://ctro/data#hasPercentageAffected> \"4\"."
39566, Percentage, 2806, 2807, "%", "", 
39546, Constipation, 2816, 2828, "constipation", "", "<http://ctro/data#Endpoint_22148> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Constipation>."
39557, PercentageAffected, 2831, 2833, "10", "", "<http://ctro/data#Outcome_22369> <http://ctro/data#hasPercentageAffected> \"10\"."
39567, Percentage, 2834, 2835, "%", "", 
39558, PercentageAffected, 2841, 2842, "2", "", "<http://ctro/data#Outcome_22396> <http://ctro/data#hasPercentageAffected> \"2\"."
39568, Percentage, 2843, 2844, "%", "", 
39547, Exenatide, 2864, 2873, "exenatide", "", 
39548, Placebo, 2884, 2891, "placebo", "", 
39569, TimePoint, 2989, 2997, "baseline", "", 
39570, HbA1c, 3072, 3090, "HbA ₁ ( c ) levels", "", 
39571, Exenatide, 3102, 3111, "exenatide", "", 
39572, Placebo, 3128, 3135, "placebo", "", 
39579, ConclusionComment, 3197, 3408, "Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .", "", "<http://ctro/data#ClinicalTrial_21739> <http://ctro/data#hasConclusionComment> \"Adding twice - daily exenatide injections improved glycemic control without increased hypoglycemia or weight gain in participants with uncontrolled type 2 diabetes who were receiving insulin glargine treatment .\"."
39573, Frequency, 3204, 3217, "twice - daily", "", 
39574, Exenatide, 3218, 3227, "exenatide", "", 
39575, Hypoglycemia, 3283, 3295, "hypoglycemia", "", 
39576, WeightGain, 3299, 3310, "weight gain", "", 
39577, Type2Diabetes, 3345, 3360, "type 2 diabetes", "", 
39578, InsulinGlargine, 3380, 3396, "insulin glargine", "", 
39580, ConclusionComment, 3409, 3506, "Adverse events of exenatide included nausea , diarrhea , vomiting , headache , and constipation .", "", 
39581, Exenatide, 3427, 3436, "exenatide", "", 
39582, Nausea, 3446, 3452, "nausea", "", 
39583, Headache, 3477, 3485, "headache", "", 
39584, Constipation, 3492, 3504, "constipation", "", 
39585, PMID, 3662, 3670, "21138825", "", "<http://ctro/data#Publication_21732> <http://ctro/data#hasPMID> \"21138825\"."
